Axsome's flagship product, AUVELITY (AXS-05), has been approved for the treatment of major depressive disorder (MDD) and is showing strong commercial performance. The company is now exploring the ...

Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after Sept. 30, 2038, if no pediatric ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity ® 4Q and full year 2024 net product sales of ...

The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...

For the year, we delivered total net product revenue of $386 million, reflecting high double-digit year-over-year growth for Auvelity and Sunosi. We expect continued growth in 2025, supported by ...

Total net product revenue reached $386 million for 2024, with CEO Tabuteau stating, "Based on the recent performance, Auvelity is on track to reach blockbuster potential." Symbravo received FDA ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...

The year-over-year increase in revenues can be attributed to strong sales of Auvelity (AXS-05). In the past year, shares of Axsome have rallied 41.3% against the industry’s decline of 8.8%.